Quality of life in metastatic prostate cancer among men of lower socioeconomic status: feasibility and criterion related validity of 3 measures.

[1]  K. Pienta,et al.  Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. , 1997, Urology.

[2]  L. Sharp,et al.  Comparison of perspectives on prostate cancer: analyses of survey data. , 1997, Urology.

[3]  J. Ware,et al.  Health-related quality of life among patients with metastatic prostate cancer. , 1997, Urology.

[4]  D. Matchar,et al.  Treatment considerations for persons with metastatic prostate cancer: survival versus out-of-pocket costs. , 1997, Urology.

[5]  D. Osoba,et al.  Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  C. Bennett,et al.  Performance measurement in prostate cancer care: beyond report cards. , 1996, Urology.

[7]  M. E. Smith,et al.  The Department of Veterans Affairs medical care system and the people it serves. , 1996, Medical care.

[8]  L. Figgs,et al.  Differences in cancer incidence, mortality, and survival between African Americans and whites. , 1995, Environmental health perspectives.

[9]  R H Brook,et al.  Quality-of-life outcomes in men treated for localized prostate cancer. , 1995, JAMA.

[10]  J. Holland,et al.  Quality of life of patients with prostate cancer and their spouses. The value of a data base in clinical care , 1994, Cancer.

[11]  D. Osoba,et al.  Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  D. Osoba,et al.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.

[13]  D. Tulsky,et al.  The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  J. Sharp.  Expanding the definition of quality of life for prostate cancer , 1993, Cancer.

[15]  H. Herr,et al.  A comparison of the quality of life of patients with metastatic prostate cancer who received or did not receive hormonal therapy , 1993, Cancer.

[16]  C. Sherbourne,et al.  The MOS 36-Item Short-Form Health Survey (SF-36) , 1992 .

[17]  A McMurray,et al.  Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  D. Karnofsky,et al.  The use of the nitrogen mustards in the palliative treatment of carcinoma. With particular reference to bronchogenic carcinoma , 1948 .

[19]  Taylor Murray,et al.  Cancer statistics, 1998 , 1998, CA: a cancer journal for clinicians.

[20]  G. Murphy,et al.  The national cancer data base report on prostate cancer , 1995 .

[21]  H. Villavicencio.  Quality of life of patients with advanced and metastatic prostatic carcinoma. , 1993, European urology.

[22]  S. Fosså,et al.  Quality of life in prostate cancer , 1992, The Prostate. Supplement.

[23]  W. Ellis,et al.  Advanced prostatic carcinoma. Early versus late endocrine therapy. , 1991, The Urologic clinics of North America.

[24]  S. Fosså,et al.  Quality of life and treatment of hormone resistant metastatic prostatic cancer , 1990 .

[25]  A. Dobson,et al.  Measuring the quality of life of cancer patients: a concise QL-index for use by physicians. , 1981, Journal of chronic diseases.